LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 60

Search options

  1. Article ; Online: Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.

    Komeno, Takashi / Furuta, Yousuke / Nakajima, Nozomi / Tani, Hideki / Morinaga, Yoshitomo

    Antiviral research

    2022  Volume 205, Page(s) 105387

    Abstract: Favipiravir (T-705, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) selectively and strongly inhibits the replication of influenza virus in vitro and in vivo. Favipiravir is converted to favipiravir-4-ribofuranosyl-5-triphosphate (favipiravir RTP) by ... ...

    Abstract Favipiravir (T-705, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) selectively and strongly inhibits the replication of influenza virus in vitro and in vivo. Favipiravir is converted to favipiravir-4-ribofuranosyl-5-triphosphate (favipiravir RTP) by intracellular enzymes and functions as a nucleotide analog to selectively inhibit RNA-dependent RNA polymerase (RdRP) of influenza virus. Our previous experiments failed in an attempt to obtain a favipiravir-resistant influenza virus in vitro using influenza virus A/PR/8/34(H1N1). Conversely, Goldhill et al. reported a favipiravir-resistant influenza virus generated by in vitro passage of influenza virus A/England/195/2009 (H1N1), an early isolate from the 2009 H1N1 pandemic (pdm09), in the presence of favipiravir with K229R mutation in PB1. This study focused on K229R mutation near the NTP cross-linked region in PB1 based on the above conflicting findings to confirm whether K229R mutation brings favipiravir resistance to influenza virus A/PR/8/34. Thirty PB1 mutants generated by site-directed mutagenesis of the NTP cross-linked region were evaluated using an influenza virus A/PR/8/34 replicon system. Among the 30 mutants, 10 possessed but 20 lost replicon activity. When susceptibility to favipiravir in 10 mutants was further assessed, the PB1 E491D mutant was five times more sensitive than the wild-type (WT), while only the PB1 K229R mutant was resistant to favipiravir. Results suggested that the evaluated region was essential for polymerase activity, and K229 mutation was responsible for polymerase inhibition of favipiravir in the influenza virus A/PR/8/34. Interestingly, the tested K229X series mutants entirely lost replicon activity, except for K229R. This suggested that the amino acid at position 229 in PB1 of influenza virus may play a pivotal role in polymerase activity. Moreover, this lysine residue is highly conserved among positive- and negative-sense single-stranded RNA viruses, in which favipiravir showed potent activity, suggesting that this mutation may determine the characterization of the in vitro broad-spectrum activity of favipiravir. Additionally, this mutation acquisition greatly influences the viral replication and the susceptibility to favipiravir.
    MeSH term(s) Amides ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Drug Resistance, Viral ; Humans ; Influenza A Virus, H1N1 Subtype ; Influenza, Human/drug therapy ; Mutagenesis, Site-Directed ; Pyrazines ; RNA-Dependent RNA Polymerase/genetics ; Virus Replication ; Viruses
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2022-08-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2022.105387
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.

    Furuta, Yousuke / Komeno, Takashi / Nakamura, Takaaki

    Proceedings of the Japan Academy. Series B, Physical and biological sciences

    2017  Volume 93, Issue 7, Page(s) 449–463

    Abstract: Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir was discovered through screening chemical library for anti- ... ...

    Abstract Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir was discovered through screening chemical library for anti-viral activity against the influenza virus by Toyama Chemical Co., Ltd. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity. Since the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action underpins a broader spectrum of anti-viral activities of favipiravir. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. These unique anti-viral profiles will make favipiravir a potentially promising drug for specifically untreatable RNA viral infections.
    Language English
    Publishing date 2017
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 161781-3
    ISSN 1349-2896 ; 0386-2208
    ISSN (online) 1349-2896
    ISSN 0386-2208
    DOI 10.2183/pjab.93.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Evaluation of a novel severe combined immunodeficiency mouse model for antiviral drug evaluation against Chandipura virus infection.

    Kitaura, Satoshi / Tobiume, Minoru / Kawahara, Madoka / Satoh, Masaaki / Kato, Hirofumi / Nakayama, Noriko / Nakajima, Nozomi / Komeno, Takashi / Furuta, Yousuke / Suzuki, Tadaki / Moriya, Kyoji / Saijo, Masayuki / Ebihara, Hideki / Takayama-Ito, Mutsuyo

    Antiviral research

    2023  Volume 213, Page(s) 105582

    Abstract: Chandipura virus (CHPV) is a negative-sense single-stranded RNA virus known to cause fatal encephalitis outbreaks in the Indian subcontinent. The virus displays tropism towards the pediatric population and holds significant public health concerns. ... ...

    Abstract Chandipura virus (CHPV) is a negative-sense single-stranded RNA virus known to cause fatal encephalitis outbreaks in the Indian subcontinent. The virus displays tropism towards the pediatric population and holds significant public health concerns. Currently, there is no specific, effective therapy for CHPV encephalitis. In this study, we evaluated a novel C.B-17 severe combined immunodeficiency (SCID) mouse model which can be used for pre-clinical antiviral evaluation. Inoculation of CHPV developed a lethal infection in our model. Plaque assay and immunohistochemistry detected increased viral loads and antigens in various organs, including the brain, spinal cord, adrenal glands, and whole blood. We further conducted a proof-of-concept evaluation of favipiravir in the SCID mouse model. Favipiravir treatment improved survival with pre-symptomatic (days 5-14) and post-symptomatic (days 9-18) treatment. Reduced viral loads were observed in whole blood, kidney/adrenal gland, and brain tissue with favipiravir treatment. The findings in this study demonstrate the utility of SCID mouse for in vivo drug efficacy evaluation and the potential efficacy of favipiravir against CHPV infection.
    MeSH term(s) Child ; Humans ; Animals ; Mice ; Antiviral Agents/therapeutic use ; Drug Evaluation ; Mice, SCID ; Severe Combined Immunodeficiency/drug therapy ; Vesiculovirus/genetics ; Encephalitis
    Chemical Substances favipiravir (EW5GL2X7E0) ; Antiviral Agents
    Language English
    Publishing date 2023-03-21
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2023.105582
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening

    Yamada, Hiroshi / Taniguchi, Satoshi / Shimojima, Masayuki / Tan, Long / Kimura, Miyuki / Morinaga, Yoshitomo / Fukuhara, Takasuke / Matsuura, Yoshiharu / Komeno, Takashi / Furuta, Yousuke / Saijo, Masayuki / Tani, Hideki

    Viruses. 2021 June 03, v. 13, no. 6

    2021  

    Abstract: Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that causes severe disease in humans with case fatality rates of approximately 30%. There are few treatment options for SFTSV infection. SFTSV RNA synthesis is ...

    Abstract Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that causes severe disease in humans with case fatality rates of approximately 30%. There are few treatment options for SFTSV infection. SFTSV RNA synthesis is conducted using a virus-encoded complex with RNA-dependent RNA polymerase activity that is required for viral propagation. This complex and its activities are, therefore, potential antiviral targets. A library of small molecule compounds was processed using a high-throughput screening (HTS) based on an SFTSV minigenome assay (MGA) in a 96-well microplate format to identify potential lead inhibitors of SFTSV RNA synthesis. The assay confirmed inhibitory activities of previously reported SFTSV inhibitors, favipiravir and ribavirin. A small-scale screening using MGA identified four candidate inhibitors that inhibited SFTSV minigenome activity by more than 80% while exhibiting less than 20% cell cytotoxicity with selectivity index (SI) values of more than 100. These included mycophenolate mofetil, methotrexate, clofarabine, and bleomycin. Overall, these data demonstrate that the SFTSV MGA is useful for anti-SFTSV drug development research.
    Keywords Huaiyangshan banyangvirus ; Orthobunyavirus ; RNA ; RNA-directed RNA polymerase ; antiviral agents ; cytotoxicity ; death ; disease severity ; drug development ; lead ; methotrexate
    Language English
    Dates of publication 2021-0603
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ZDB-ID 2516098-9
    ISSN 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v13061061
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: Administration of the antiviral agent T-1105 fully protects pigs from foot-and-mouth disease infection.

    Nishi, Tatsuya / Fukai, Katsuhiko / Masujin, Kentaro / Kawaguchi, Rie / Ikezawa, Mitsutaka / Yamada, Manabu / Nakajima, Nozomi / Komeno, Takashi / Furuta, Yousuke / Sugihara, Hiromi / Kurosaki, Chie / Sakamoto, Kenichi / Morioka, Kazuki

    Antiviral research

    2022  Volume 208, Page(s) 105425

    Abstract: Foot-and-mouth disease (FMD) is a contagious disease affecting cloven-hoofed animals. Its transmissibility and antigenic variety make this disease difficult to control. Antiviral agents are expected to have an immediate effect that is independent of ... ...

    Abstract Foot-and-mouth disease (FMD) is a contagious disease affecting cloven-hoofed animals. Its transmissibility and antigenic variety make this disease difficult to control. Antiviral agents are expected to have an immediate effect that is independent of viral antigenicity; thus, they can serve as effective tools for inhibiting the spread of the causative agent, the FMD virus (FMDV), from infected animals. In this study, we investigated the antiviral activity of a pyrazinecarboxamide derivative, T-1105, against FMDV. Cytopathic effect inhibition assays revealed that T-1105 strongly inhibited the replication of 28 reference strains of all seven FMDV serotypes at non-cytotoxic concentrations. The antiviral effect of T-1105 against FMDV was also evaluated by experimental infection of domestic pigs. T-1105 was administered orally to pigs starting 1 h before or 6 h after the inoculation of a porcinophilic FMDV serotype O, topotype CATHAY. None of the pigs administered with T-1105 showed clinical signs of FMD. Moreover, no infectious FMDVs or FMDV-specific genes were detected in their sera, oral and nasal discharges, or tissues collected 48 h after virus inoculation. These findings strongly suggest that administration of T-1105 is effective in controlling the spread of FMDV in pigs.
    MeSH term(s) Swine ; Animals ; Foot-and-Mouth Disease/drug therapy ; Foot-and-Mouth Disease/prevention & control ; Antiviral Agents/therapeutic use ; Foot-and-Mouth Disease Virus ; Pyrazines/pharmacology
    Chemical Substances T 1105 ; Antiviral Agents ; Pyrazines
    Language English
    Publishing date 2022-09-28
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2022.105425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus.

    Julander, Justin G / Dagley, Ashley / Gebre, Makda / Komeno, Takashi / Nakajima, Nozomi / Smee, Donald F / Furuta, Yousuke

    Antiviral research

    2020  Volume 182, Page(s) 104904

    Abstract: Antiviral countermeasures are needed to reduce the morbidity associated with Chikungunya virus (CHIKV) infection. This arbovirus reemerged in 2004 and causes periodic outbreaks in various areas throughout the world. While infection is rarely lethal, the ... ...

    Abstract Antiviral countermeasures are needed to reduce the morbidity associated with Chikungunya virus (CHIKV) infection. This arbovirus reemerged in 2004 and causes periodic outbreaks in various areas throughout the world. While infection is rarely lethal, the majority of people infected with the virus develop a hallmark arthralgia as well as other disease manifestations. The virus is classified within three phylogenetic groups, namely, West African, East/Central/South African (ECSA), and Asian. Six strains of CHIKV covering the three phylogenetic groups were studied for their replication in cell culture, their ability to cause disease in susceptible mouse strains and susceptibility to antiviral treatment. Differential replication kinetics were observed for various CHIKV isolates in cell culture, which coincided with a decreased sensitivity to antiviral treatment as compared with ECSA and Asian clade viruses. This was confirmed in mouse infection studies with severe disease observed in mice infected with West African clade viruses, mild disease phenotype after infection with Asian clade viruses and an intermediate disease severity associated with ECSA virus infection. We also tested a broadly active antiviral, Favipiravir (T-705), which activity was inversely proportional to disease severity. These data suggest that some clades of CHIKV may cause more severe disease and may be more difficult to treat.
    MeSH term(s) Amides/therapeutic use ; Animals ; Antiviral Agents/therapeutic use ; Cell Line ; Chikungunya Fever/drug therapy ; Chikungunya Fever/virology ; Chikungunya virus/classification ; Chikungunya virus/drug effects ; Chikungunya virus/pathogenicity ; Female ; Genotype ; Humans ; Mice ; Mice, Inbred DBA ; Phenotype ; Phylogeny ; Pyrazines/therapeutic use
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2020-08-10
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2020.104904
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients.

    Hickerson, Brady T / Westover, Jonna B / Jung, Kie-Hoon / Komeno, Takashi / Furuta, Yousuke / Gowen, Brian B

    The Journal of infectious diseases

    2018  Volume 218, Issue 4, Page(s) 522–527

    Abstract: Lymphocytic choriomeningitis virus (LCMV) poses a substantial risk to immunocompromised individuals. The case fatality rate in recent clusters of LCMV infection in immunosuppressed organ transplantation recipients has exceeded 70%. In the present study, ... ...

    Abstract Lymphocytic choriomeningitis virus (LCMV) poses a substantial risk to immunocompromised individuals. The case fatality rate in recent clusters of LCMV infection in immunosuppressed organ transplantation recipients has exceeded 70%. In the present study, we demonstrate potent antiviral activity of favipiravir against acute, disseminated LCMV infection in NZB mice. Treatment resulted in complete protection against mortality and dramatic reductions in viral loads. In contrast, ribavirin, the current antiviral of choice, was mostly ineffective. Our findings, and the high lethality associated with LCMV infection in transplant recipients, support the consideration of favipiravir as a first-line therapeutic option.
    MeSH term(s) Amides/administration & dosage ; Animals ; Antiviral Agents/administration & dosage ; Disease Models, Animal ; Female ; Immunocompromised Host ; Lymphocytic Choriomeningitis/drug therapy ; Lymphocytic Choriomeningitis/virology ; Lymphocytic choriomeningitis virus/isolation & purification ; Male ; Mice, Inbred NZB ; Pyrazines/administration & dosage ; Ribavirin/administration & dosage ; Survival Analysis ; Transplant Recipients ; Treatment Outcome ; Viral Load
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; Ribavirin (49717AWG6K) ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2018-05-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiy159
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Susceptibility of Type I Interferon Receptor Knock-Out Mice to Heartland Bandavirus (HRTV) Infection and Efficacy of Favipiravir and Ribavirin in the Treatment of the Mice Infected with HRTV.

    Fujii, Hikaru / Tani, Hideki / Egawa, Kazutaka / Taniguchi, Satoshi / Yoshikawa, Tomoki / Fukushi, Shuetsu / Yamada, Souichi / Harada, Shizuko / Kurosu, Takeshi / Shimojima, Masayuki / Maeki, Takahiro / Lim, Chang-Kweng / Takayama-Ito, Mutsuyo / Komeno, Takashi / Nakajima, Nozomi / Furuta, Yousuke / Uda, Akihiko / Morikawa, Shigeru / Saijo, Masayuki

    Viruses

    2022  Volume 14, Issue 8

    Abstract: Heartland bandavirus (HRTV) is an emerging tick-borne virus that is distributed in the United States and that causes febrile illness with thrombocytopenia and leukocytopenia. It is genetically close to Dabie bandavirus, which is well known as severe ... ...

    Abstract Heartland bandavirus (HRTV) is an emerging tick-borne virus that is distributed in the United States and that causes febrile illness with thrombocytopenia and leukocytopenia. It is genetically close to Dabie bandavirus, which is well known as severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV). The mortality rate of human HRTV infection is approximately 10%; however, neither approved anti-HRTV agents nor vaccines exist. An appropriate animal model should be developed to evaluate the efficacy of antiviral agents and vaccines against HRTV. The susceptibility of IFNAR
    MeSH term(s) Amides ; Animals ; Disease Models, Animal ; Humans ; Mice ; Mice, Knockout ; Phlebovirus ; Pyrazines ; Receptor, Interferon alpha-beta/genetics ; Ribavirin/therapeutic use ; Solvents ; Thrombocytopenia
    Chemical Substances Amides ; Pyrazines ; Solvents ; Receptor, Interferon alpha-beta (156986-95-7) ; Ribavirin (49717AWG6K) ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2022-07-28
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14081668
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.

    Yamada, Kentaro / Noguchi, Kazuko / Komeno, Takashi / Furuta, Yousuke / Nishizono, Akira

    The Journal of infectious diseases

    2015  Volume 213, Issue 8, Page(s) 1253–1261

    Abstract: Rabies is a fatal encephalitis caused by rabies virus (RABV), and no antiviral drugs for RABV are currently available. We report for the first time the efficacy of favipiravir (T-705) against RABV in vitro and in vivo. T-705 produced a significant, 3-4 ... ...

    Abstract Rabies is a fatal encephalitis caused by rabies virus (RABV), and no antiviral drugs for RABV are currently available. We report for the first time the efficacy of favipiravir (T-705) against RABV in vitro and in vivo. T-705 produced a significant, 3-4 log10 reduction in the multiplication of street and fixed RABV strains in mouse neuroblastoma Neuro-2a cells, with half-maximal inhibitory concentrations of 32.4 µM and 44.3 µM, respectively. T-705 significantly improved morbidity and mortality among RABV-infected mice when orally administered at a dose of 300 mg/kg/day for 7 days, beginning 1 hour after inoculation. T-705 significantly reduced the rate of virus positivity in the brain. Furthermore, the effectiveness of T-705 was comparable to that of equine rabies virus immunoglobulin for postexposure prophylaxis. Collectively, our results suggest that T-705 is active against RABV and may serve as a potential alternative to rabies immunoglobulin in rabies postexposure prophylaxis.
    MeSH term(s) Amides/administration & dosage ; Amides/pharmacology ; Amides/therapeutic use ; Animals ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Cell Line ; Disease Models, Animal ; Mice ; Post-Exposure Prophylaxis/methods ; Post-Exposure Prophylaxis/statistics & numerical data ; Pyrazines/administration & dosage ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; Rabies/drug therapy ; Rabies/virology ; Treatment Outcome ; Viral Load/drug effects
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2015-12-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiv586
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus.

    Kato, Hirofumi / Takayama-Ito, Mutsuyo / Satoh, Masaaki / Kawahara, Madoka / Kitaura, Satoshi / Yoshikawa, Tomoki / Fukushi, Shuetsu / Nakajima, Nozomi / Komeno, Takashi / Furuta, Yousuke / Saijo, Masayuki

    PLoS neglected tropical diseases

    2021  Volume 15, Issue 7, Page(s) e0009553

    Abstract: Background: Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, primarily in North American adults. Currently, there are no available vaccines or specific treatments ... ...

    Abstract Background: Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, primarily in North American adults. Currently, there are no available vaccines or specific treatments against JCV infections.
    Methodology/principal findings: The antiviral efficacy of favipiravir (FPV) against JCV infection was evaluated in vitro and in vivo in comparison with that of ribavirin (RBV) and 2'-fluoro-2'-deoxycytidine (2'-FdC). The in vitro inhibitory effect of these drugs on JCV replication was evaluated in Vero and Neuro-2a (N2A) cells. The efficacy of FPV in the treatment of JCV infection in vivo was evaluated in C57BL/6J mice inoculated intracerebrally with JCV, as per the survival, viral titers in the brain, and viral RNA load in the blood. The 90% inhibitory concentrations (IC90) of FPV, RBV, and 2'-FdC were 41.0, 61.8, and 13.6 μM in Vero cells and 20.7, 25.8, and 8.8 μM in N2A cells, respectively. All mice infected with 1.0×104 TCID50 died or were sacrificed within 10 days post-infection (dpi) without treatment. However, mice treated with FPV for 5 days [initiated either 2 days prior to infection (-2 dpi-2 dpi) or on the day of infection (0 dpi-4 dpi)] survived significantly longer than control mice, administered with PBS (p = 0.025 and 0.011, respectively). Moreover, at 1 and 3 dpi, the virus titers in the brain were significantly lower in FPV-treated mice (0 dpi-4 dpi) versus PBS-treated mice (p = 0.002 for both 1 and 3 dpi).
    Conclusions/significance: Although the intracerebral inoculation route is thought to be a challenging way to evaluate drug efficacy, FPV inhibits the in vitro replication of JCV and prolongs the survival of mice intracerebrally inoculated with JCV. These results will enable the development of a specific antiviral treatment against JCV infections and establishment of an effective animal model.
    MeSH term(s) Amides/administration & dosage ; Animals ; Antiviral Agents/administration & dosage ; Chlorocebus aethiops ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Encephalitis Virus, California/drug effects ; Encephalitis Virus, California/genetics ; Encephalitis Virus, California/growth & development ; Encephalitis, California/drug therapy ; Encephalitis, California/mortality ; Encephalitis, California/virology ; Female ; Humans ; Mice ; Mice, Inbred C57BL ; Pyrazines/administration & dosage ; Vero Cells
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; favipiravir (EW5GL2X7E0)
    Language English
    Publishing date 2021-07-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2429704-5
    ISSN 1935-2735 ; 1935-2727
    ISSN (online) 1935-2735
    ISSN 1935-2727
    DOI 10.1371/journal.pntd.0009553
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top